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Abstract: Drug resistance remains a major challenge in the treatment of cancer. The multiplicity
of the drug resistance determinants raises the question about the optimal strategies to deal with
them. Essential oils showed to inhibit the growth of different tumor cell types. Essential oils contain
several chemical classes of compounds whose heterogeneity of active moieties can help prevent the
development of drug resistance. In the present paper, we analyzed, by gas chromatography-mass
spectrometry the chemical composition of the essential oil of the leaves of Kalanchoe beharensis
obtained by hydrodistillation and compared the chemical composition of its essential oil with that
of Cyphostemma juttae. Our results demonstrated the anticancer and proapoptotic activities of both
species against acute myeloid leukemia on an in vitro model and its multidrug resistant variant
involving NF-κB pathway. The essential oils of both species produced a significant decrease in many
targets of NF-κB both at mRNA and protein levels. The results corroborate the idea that essential
oils may be a good alternative to traditional drugs in the treatment of cancer, especially in drug
resistant cancer.
Keywords: acute myeloid leukemia cell; Cyphostemma juttae; essential oil; Kalanchoe beharensis;
multidrug resistance; NF-κB
1. Introduction
Clinical multidrug resistance is a multifactorial and heterogeneous process that strongly limits
the efficacy of antitumor drugs. Drug resistance, especially in its multiple type (MDR), remains
a major challenge in the treatment of cancer. Resistance can develop by numerous mechanisms,
including decreased drug uptake, increased drug efflux, activation of detoxifying systems, activation
of DNA repair mechanisms, evasion of drug-induced apoptosis, elevated autophagy, and/or altered
drug metabolism [1]. One of the determining causes is the overexpression of multidrug efflux
transporters, such as P-glycoprotein (P-gp), Multidrug Resistance Related Proteins (MRPs) or Breast
Cancer Resistance Protein (BCRP) [2,3]. Moreover, loss of pro-apoptotic factors (e.g., p53 or Bax) or
overexpression of anti-apoptotic factors, such as Bcl-2 or inhibitors of apoptosis proteins (IAPs) may
interfere with the induction of tumor cell killing determining the inefficacy of anticancer drugs [4].
More recently, the constitutive expression of NF-κB factor was also related to MDR [5]. In acute myeloid
leukemia (AML), constitutive NF-κB has been detected in more than 50% of cases, enabling leukemic
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cells to resist apoptosis and stimulate uncontrolled proliferation [6]. Therefore, NF-κB is considered
as a poor prognostic factor in different types of cancer, and its inhibition can lead to pro-apoptotic
signal activation and pro-survival response suppression [7,8]. All these observations demonstrate the
importance of NF-κB as a therapeutic target [9]. The multiplicity of the drug resistance determinants
raises the question about the optimal strategies to deal with them. There is a need for new agents that
are more effective and able to bypass resistance with respect to conventional ones. In this context,
essential oils (EOs) inhibit the growth of different tumor cell types. EOs contain several chemical classes
of compounds whose heterogeneity of active moieties can help avoid the development of resistances.
Previous works demonstrated that EOs, among others, have antitumor activities on different types
of tumors, such as hepatocellular carcinoma, triple negative breast cancer [10,11] and acute myeloid
leukemia (AML) [12] all characterized by scarce responsiveness to chemotherapeutic drugs.
The genus Kalanchoe Adanson (Crassulaceae) contains approximately 150 species distributed
mainly in Madagascar, South Africa, eastern Africa, and Asia. Kalanchoe can have diverse forms, such as
shrubs, small trees, lianas and small epiphytes both having succulent leaves [13,14]. Half of Kalanchoe
species are native to Madagascar [15]. Kalanchoe plants have had a long history in folk medicine, and
according to Akulova-Barlow [16], some have been called “miracle leaf” for their remarkable healing
properties. Cytotoxic activity was tested in tumor cell lines by Yamagishi [17] and Shirobokov [18] and
indicated that the juice of 12 species has antiviral or neutralizing activity against viruses. A review
by Milad et al. [19] reported that Kalanchoe spp. have several pharmacological activities, for example:
Antiviral, sedative, antiulcer, immunomodulatory, antileishmanial, CNS depressant, anti-inflammatory,
thyroid peroxidase inhibitor, cytotoxic, hepatoprotective, antioxidant, analgesic, anticonvulsant,
antimicrobial, B cell development inhibitor, cardiovascular activity, antihyperglycemic, larvicidal and
insecticidal. In contrast to the extensively studied herbaceous Kalanchoe species, Kalanchoe beharensis is a
large evergreen shrub up to 3 m tall of the xerophytic bush in southern Madagascar [20,21]. The leaves
of the plant locally known as “mongy” are used in traditional medicine as a laxative [22,23], and
occasionally consumed by the ring-tailed lemur [24,25].
From the chemical point of view, Kalanchoe spp. are composed of flavonoid glycosides,
anthocyanins, coumarins, bufadienlolides, triterpenoids, phenanthrenes, sterols, fatty acids and
kalanchosine dimalate salt [19]. However, the single chemical study was done by Ghaly et al. [26],
which reported the isolation of five different flavonoids from the methanolic extracts of K. beharensis
(Figure 1). To the best of our knowledge, there are no papers published on EO in the whole
genus Kalanchoe.
The genus Cyphostemma (Planch.) Alston (Vitaceae) includes about 150 species distributed in
eastern and southern Africa and Madagascar, and some species are used in traditional medicine [27].
The antiproliferative effects of solvent extracts of some Cyphostemma spp. on HepG2 cell line have been
reported by Opoku et al. [28]. Recently, Zito et al. [11] demonstrated that the EO of Cyphostemma juttae
has antitumor activities in triple negative breast cancer cells (MDA-MB-231, SUM 149).
In the present paper we analyzed, by gas chromatography-mass spectrometry (GC-MS),
the chemical composition of the essential oil of the leaves of Kalanchoe beharensis obtained by
hydrodistillation (HD) and compared the chemical composition of its EO with that of Cyphostemma
juttae. We also evaluated if the cytotoxic activity of both species against AML in vitro model and its
MDR variant involved NF-κB pathway. Previous papers [29,30] highlighted that HL-60R cells are
characterized by an overexpression of NF-κB, P-gp and IAPs. In particular, P-gp and IAPs are targets of
NF-κB and are also involved in drug and apoptosis resistance. IAPs, which are endowed with different
activities, have also shown a remarkable ability to block apoptosis induced by a wide spectrum of
non-related triggers, including different anti-tumor agents [30,31]. For these reasons, we selected these
NF-κB target genes to investigate their expression after EOs treatment.
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2. Results
2.1. Chemical Composition
The essential oil yield was 15.21 mg (0.003%). In the sse tial oil of Kalanchoe beharen is, we
identified 57 comp unds (87% of the whole composition) belonging to 14 different classes and functional
groups of compounds (Tabl 1). Only compounds which h d mass pectral si ilarity ≥80% with
respect to our libraries were consid red.
Overall, the compositi n was dominated by diterpene alcohols with 35.6%, followed by
aliphatic alkanes (14.3%), aliphatic alcohols (11.1%) and sesquiterpene hydrocarbons (10.7%).
The most abu dant compounds (≥ 5%) were phytol (35%; Figure 2), tetradecanoic acid (5.1%),
(Z,Z,Z)-9,12,15-octadecatrien-1-ol (5.1%), and heptacosane (5%) cont ibuting to ether 50.2% of the total
compositio . Eleven comp un s were detected in relativ amounts between 1 and 5%, wh reas 42
compounds wer found in amounts < 1% (Table 1).
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Table 1. Essential oil composition of Kalanchoe beharensis. Compounds belonging to the same chemical
class and functional group [32] are arranged according to Kovats Retention Indices (KRI) of the
Supelcowax 10 column.
RI a Ident b Compound Relative Amount (%) MSS c (%)
Aliphatic Acids
2720 RI, MS Tetradecanoic Acid 5.1 94
Aliphatic Alcohols
1354 RI, MS Hexanol 0.2 95
1407 RI, MS (E)-2-Hexen-1-ol 0.1 88
1452 RI, MS 1-Octen-3-ol 1.3 95
1558 RI, MS Octanol 1.5 97
1616 RI, MS (E)-2-Octen-1-ol 1.0 91
1661 RI, MS Nonanol 0.1 88
1761 MS (Z)-9-Tetradecen-1-ol 0.2 87
1763 RI, MS Decanol 0.1 87
1968 RI, MS Dodecanol 0.2 88
2174 RI, MS Tetradecanol 0.3 83
2585 RI, MS Octadecanol 0.4 90
2793 MS Eicosanol 0.8 91
2816 MS (Z,Z,Z)-9,12,15-Octadecatrien-1-ol 5.1 85
Aliphatic Aldehydes
1050 RI, MS Hexanal 0.5 92
1218 RI, MS (E)-2-Hexenal 0.7 95
1389 RI, MS Nonanal 0.4 96
1494 RI, MS Decanal 0.6 95
2023 RI, MS Pentadecanal 0.5 90
2129 RI, MS Hexadecanal 0.1 89
Aliphatic Alkanes*
1400 RI, MS, Co-GC Tetradecane 0.1 standard
1700 RI, MS, Co-GC Heptadecane 0.04 standard
1900 RI, MS, Co-GC Nonadecane 0.2 standard
2200 RI, MS, Co-GC Docosane 0.4 standard
2300 RI, MS, Co-GC Tricosane 2.4 standard
2500 RI, MS, Co-GC Pentacosane 3.6 standard
2600 RI, MS, Co-GC Hexacosane 0.7 standard
2700 RI, MS, Co-GC Heptacosane 5.0 standard
2900 RI, MS, Co-GC Nonacosane 1.8 standard
Aliphatic Alkenes
1862 MS (Z,Z,Z)-3,6,9-Tetradecatriene 0.6 87
Aliphatic Esters
1607 RI, MS Hexyl hexanoate 0.1 86
2213 RI, MS Methyl palmitate 0.1 88
Aromatic Esters
2164 MS 2-Ethylhexyl benzoate 0.1 93
2286 MS 2-Ethylhexyl salicylate 0.2 80
Diterpene Alcohols
2296 RI, MS Isophytol 0.6 88
2615 RI, MS Phytol 35.0 96
Irregular terpene Ketones
1807 RI, MS (E)-β-Damascenone 0.2 83
2123 RI, MS Hexahydrofarnesyl acetone 4.1 94
Monoterpene Alcohols
1789 RI, MS α-Campholenol 0.1 84
2216 RI, MS Carvacrol 0.2 91
Monoterpene Ketones
1630 RI, MS Pulegone 0.5 95
1908 RI, MS Piperitenone 0.6 86
Sesquiterpene Alcohols
1552 RI, MS (Z)-Sesquisabinene hydrate 0.2 86
2042 RI, MS (E)-Nerolidol 0.1 83
2308 MS 6-epi-Shyobunol 0.2 83
Sesquiterpene Ethers
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Table 1. Cont.
RI a Ident b Compound Relative Amount (%) MSS c (%)
1956 RI, MS Caryophyllene oxyde 0.4 92
Sesquiterpene Hydrocarbons
1470 RI, MS α-Copaene 0.2 94
1572 RI, MS β-Caryophyllene 4.5 97
1644 RI, MS α-Humulene 0.1 85
1665 MS (E)-β-Bergamotene 0.04 83
1696 RI, MS γ-Humulene 0.1 85
1736 RI, MS δ-Cadinene 0.1 85
1926 RI, MS Neophytadiene 2.8 94
1955 MS Neophytadiene isomer # 1.1 95
1982 MS Neophytadiene isomer # 1.4 95
2236 MS Neophytadiene isomer # 0.3 86
a RI = Experimental for Supelcowax 10 capillary column (30 m long, 0.25 mm i.d., 0.25 µm film thickness). b Ident.: RI
= NIST Standard Reference Database for polar capillary columns; MS = identification based on comparison of Mass
Spectra; Co-GC = Co-injection of authentic compounds. c MSS: Mass Spectrum Similarity. # isomer not identified.
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the present study, K. beharensis contains 35% of phytol. Interestingly, also sesquiterpene 
hydrocarbons were present in both species with high percentages (10.6% in K. beharensis and 13.9% 
in C. juttae) (Figure 3). 
Figure 2. Mass spectrum and chemical structure of phytol found in the present study.
Zito et al. [11] found that the EO of C. juttae contained 34.2% of phytol and its isomer, while in the
present study, K. beharensis contains 35% of phytol. Interestingly, also sesquiterpene hydrocarbons were
present in both species with high percentages (10.6% in K. beharensis and 13.9% in C. juttae) (Figure 3).
2.2. Cytotoxic Effects of C. juttae and K. beharensis Essential Oils
Cell growth inhibition assays revealed that the cytotoxic activity of C. juttae and K. beharensis
essential oils on HL-60 cell line and on its MDR variant HL-60R cell line is quite equivalent.
As shown in Figure 4A,B after 72 h of treatment, both essential oils induced cell growth inhibition
at concentration-dependent way in the two cell lines; in Table 2 are reported the IC50 of C. juttae and
K. beharensis essential oils. The treatment of the cell lines with doxorubicin, which is a conventional
chemotherapeutic agent used as a first line treatment in AML, caused a cytotoxic effect with IC50
values of 8 ± 0.4 ng/mL and 1.2 ± 0.3 µg/mL for HL-60 and HL-60R, respectively. The IC50 values of
EOs in both cell lines are very similar, while as expected doxorubicin must be present at very high
concentrations to obtain IC50. For this reason, we suppose that EOs were not substrates of P-gp as
doxorubicin is.
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Table 2. IC50 values of the two cell lines treated with the essential oils of C. juttae and K. beharensis.
HL-60 HL-60R
IC50 IC50
C. juttae EO 22.0 ± 0.3 µg/mL 36 ± 1.2 µg/mL
K. beharensis EO 25.0 ± 0.6 µg/mL 36.5 ± 0.3 µg/mL
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The results on cell death were confirmed by flow cytometry assessments (Figure 5). The HL-60 
and HL-60R cell lines were incubated with the essential oils (40 μg/mL) of C. juttae or K. beharensis for 
24 h, and thereafter, cell death was evaluated by flow cytometry analysis of cell DNA stained with 
propidium iodide. The results are in agreement with the cytotoxicity data, highlighting that both oils 
are capable of inducing cell death even in MDR variant cell line. In particular, the essential oil of K. 
beharensis caused a marked block in the preG0-G1 position comparable in HL-60 and HL-60R cells 
(Figure 6). 
 
Figure 5. Induction of cell death by C. juttae or K. beharensis oils in HL-60 and HL-60 R cells. 
Figure 4. Cytotoxic activity of C. juttae (A) and K. beharensis (B) essential oils (Eos) on leukemia HL-60
and HL-60R cell lines. Cell viability was assessed by MTS. Data are expressed as mean ± standard error
of at least three different experiments performed in triplicate. Different letters represent significant
differences (Tukey test) in cytotoxic activity among the concentrations of each cell line (C. juttae: HL-60
p < 0.01 and HL-60R p < 0.05; K. beharensis: HL-60 p < 0.05 and HL-60R p < 0.01). Differences when
treatments are compared to the controls: * p < 0.05; ** p < 0.01.
The results on cell death were confirmed by flow cytometry assessments (Figure 5). The HL-60
and HL-60R cell lines were incubated with the essential oils (40 µg/mL) of C. juttae or K. beharensis for
24 h, and thereafter, cell death was evaluated by flow cytometry analysis of cell DNA stained with
propidium iodide. The results are in agreement with the cytotoxicity data, highlighting that both oils
are capable of inducing cell death even in MDR variant cell line. In particular, the essential oil of K.
beharensis caused a marked block in the preG0-G1 position comparable in HL-60 and HL-60R cells
(Figure 6).
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Figure 6. A representative example of flow cytometry analysis of cell death and cell cycle in the HL-60
and HL-60 R cells treated with 40 µg/mL concentrations of C. juttae or K. beharensis essential oils.
The cells were incubated with 40 µg/mL concentrations of C. juttae or K. beharensis essential oil
for 24 h and thereafter cell death was evaluated by flow cytometry analysis of cell DNA stained with
propidium iodide. Data are the mean ± standard error of three separate experiments. Different letters
represent significant differences in cytotoxic activity among the two essential oils of each cell line
(HL-60 p < 0.01; HL-60 R p < 0.01). *Differences when treatments are compared to the control p < 0.01
(Tukey test).
The figure shows the profiles of propidium iodide stained DNA. Numbers in the panels indicate
the % of the events in the preG0-G1 position.
2.3. Effects of Essential Oils on NF-κB (p65 subunit) Pathway in HL-60/HL-60R Cells
In order to evaluate if C. juttae and K. beharensis essential oils could interfere on NF-κB DNA
binding capacity, HL-60 and HL-60R cell lines were treated with the two essential oils at a concentration
of 40 µg/mL for 24 h.
According to the results previously published [29], the HL-60 cells showed a very slight DNA
binding capacity of the p65 subunit. Otherwise, the HL-60R cells showed remarkable levels of the
activated p65 subunit and both essential oils of C. juttae and K. beharensis etermined a considerable
decrease of its binding capacity to the corresponding DNA consensus sequence (Figure 7).
The cells were treated for 24 h with C. juttae or K. beharensis essential oils (40 µg/mL). Results
(mean ± standard error of two experiments carried out in duplicate) are expressed as arbitrary units/µg
protein of cells nuclear extracts. Different letters represent significant differences (p < 0.05) among the
two essential oils. *Differences when treatments are compared to the control p < 0.01 (Tukey test).
Given these results, we investigated if the treatment with essential oils at the same conditions also
modified the expression of some NF-κB targets, at mRNA and protein levels in the MDR variant cell
line. The most considerable result indicated a strong reduction in some IAPs as survivin and XIAP,
Bcl-2 and P-gp expression by both essential oils (Figure 8). These results are also confirmed at protein
levels; essential oils of C. juttae and K. beharensis, in fact, produced a strong reduction of the three
anti-apopototic proteins, more evident for C. juttae EO (Figure 9).
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3. Discussion
Terpenes are known as molecules with high biological activities, and there is a wide literature
as regards to phytol activities [33]. These compounds are widely present in plants and play a key
role in their constitutive defenses [34]. The chemical composition of the two species prompted us to
verify if their EOs have comparable activity in the human AML cell line, HL-60, and its multidrug
resistant, P-gp over-expressing variant, HL-60R. The two essential oils caused cytotoxicity in HL-60
and noteworthy also on HL-60R cells, regarding cell growth inhibition and induction of cell death.
The variant HL-60R was obtained treating HL-60 cells with doxorubicin (for details see Material
and Methods section), and its molecular characterization was carried out previously [29,30]. This is
an important model of multidrug resistant cancer because HL-60R exhibits resistance to apoptosis
induced from numerous drugs, substrates of P-gp, and also from other molecules not related to the
multidrug transporter. Furthermore, HL-60R overexpress many IAPs and on the contrary of their
parental cell line, HL-60, contained and overexpress p65 subunit that is fundamental to form active
transcriptional factor NF-kappaB. The role of this transcriptional factor is well confirmed in numerous
types of cancer [35], related to all phases of cancer develop as tumorigenesis, progression, invasion
and metastasis, and its overexpression can cause the aberrant expression of the protein responsible
of multidrug resistance [5,36]. For these reasons, NF-κB is often studied as a potential target for the
treatment of malignant tumors [37–39], including AML [40] for which the therapeutic choice is restricted
to few anti-blastic drugs towards which cancer cells develop early resistance. Most recently, new
research is being conducted towards checkpoint inhibitors and cancer immunotherapy, like CAR T-cell
therapy, but the side effects are multiple and sometimes characterized by unacceptable toxicity [41].
For these reasons, the need for good alternative therapies is urgent. Furthermore, the phenomenon of
acquired resistance narrows even more therapeutic possibilities. The most common mechanism for
acquisition of resistance is the expression of energy-dependent transporters as ATP binding cassette
(ABC) transporters, characterized by homologous ATP-binding, and large, spanning transmembrane
domains, including P-gp [1]. In light of this evidence, appears even more significant our result
about inhibition of NF-κB activation from essential oils in HL-60 R cells. To further confirm that
the transcriptional factor can be an effective pharmacological target, we demonstrated that essential
oils produced a significant decrease in many targets of NF-κB both at mRNA and protein levels.
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These targets are just those responsible for resistance to apoptosis induced from drugs (IAPs) and
the multidrug transporter, P-gp. We have already reported that, in comparison to HL-60, HL-60R
cells exhibit an increased expression of some IAP family members [29,30]. However, different factors
involved in apoptosis, such as IAPs can be altered in cancer cells, thereby rendering them less prone to
drug-induced cell death. Our results demonstrated that the EOs inhibited the growth and induced cell
death by the suppression of signaling of the transcription factor NF-κB and by the suppression of IAP
family proteins and the antiapoptotic factor Bcl-2. We propose, according to the literature [42,43] the
fundamental role of NF-κB, P-gp and IAPs as possible therapeutic targets.
Defense in plants is usually constitutive, and they have mechanical or chemical defenses that can
discourage and fight phytophagous insects and microorganisms attack. Drugs widely used in the
treatment of several human and animal diseases are often chemicals involved in plant defense. Among
plants, the chemical compounds of essential oils play a key role in constitutive defense [34,44]. It is
interesting to note that the EOs of the two species investigated in the present study interfere with the
NF-κB factor. NF-κB is a conservative gene evolved one billion years ago [45] which play a key role
in the innate immunity of insects, among others [46]. EOs obtained from some plant species inhibit
the constitutive activation of NF-κB expressed in some MDR human cell lines. This mechanism may
involve NF-κB functioning in insects and may explain the selective advantage for plants to produce
such compounds which may damage the innate immunity of phytophagous insects and weakening
their fitness. The presence of phytol as the major compound in the EOs of C. juttae [11] and K. beharensis
(present study) may indicate that this compound is responsible for the NF-κB inhibition.
4. Material and Methods
4.1. Plant Species
Kalanchoe beharensis Drake (Crassulaceae) is an endemic species of the xerophytic forests of
southern Madagascar. This species, reaching about 3 m in height, has stems with leaves crowded at
the branch tips. Since its leaves (12–35 cm long and 7–35 cm wide) are covered in a dense felt it is
commonly known as Felt Plant or Elephant Ear [16].
Cyphostemma juttae (Dinter and Gilg) Desc. (Vitaceae) is a tree-like succulent growing in Namibia
and it is adapted to dry habitat. Leaves are deciduous and are produced in Summer during the
vegetative season.
4.2. Plant Material
Leaves of K. beharensis were collected in July 2018 from plants cultivated at the Botanical Garden
of the University of Palermo. The plants were raised from seeds in 1984 and cultivated in the open with
reference code: Crassulaceae N 39. Leaves of C. juttae were collected in July 2017 at the Botanical garden.
The seeds of both species were obtained, and the plants raised before the Convention on Biological
Diversity (CBD) entered into force on 29 December 1993, and therefore, are pre-CBD specimens.
The matrices were placed in paper bags and kept at −30 ◦C for 24 h before hydrodistillation. No specific
permits were required for the described location and for the collection of plant material because the
plants are part of the living collection of the Botanical Garden of the University of Palermo and the
authors have access to that.
4.3. Essential Oil Extraction
Leaves (507 g) were hand-cut into small pieces (~2 cm) and hydrodistilled for 3 h in a Clevenger-type
apparatus, using n-pentane as collection solvent [47]. The oil was dried by anhydrous sodium sulphate
and stored at −30 ◦C until chemical analysis and pharmacological tests. To prepare the stock solution
for biological studies, 2 mg of essential oil was dissolved in 1 mL of dimethyl sulfoxide (DMSO).
C. Juttae EO was obtained from the same batch of Zito et al. [11].
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4.4. Gas Chromatography-Mass Spectrometry
The essential oil of K. beharensis was analyzed by GC-MS on a single quadrupole Shimadzu
GC-MS-QP2010 Plus equipped with an AOC-20i autoinjector (Shimadzu, Kyoto, Japan) and a
Supelcowax 10 capillary column (30 m long, 0.25 mm i.d., 0.25 µm film thickness) (Merck KGaA,
Darmstadt, Germany). One µL of diluted samples (1/100 v/v, in n-pentane) was injected at 250 ◦C
in a split ratio of 1:1, and the column flow (carrier gas: Helium) was set at 1 mL/min. The GC oven
temperature was held for 5 min at 40 ◦C, then increased by 2 ◦C/min to 180 ◦C, held for 60 min and
finally raised to 240 ◦C at 10 ◦C/min. The MS interface worked at 280 ◦C, and the ion source at 250 ◦C.
Mass spectra was taken at 70 eV (in EI mode) from m/z 30 to 600. The GC/MS data were analyzed
using the GCMSolution package, Version 4.11.
The chemical analysis of C. juttae was performed by GC-MS on a Shimadzu GC-MS-QP2010 Ultra
equipped with an AOC-20i autoinjector (Shimadzu, Kyoto, Japan) and a ZB-5 fused silica column
(30 m long, 0.32 mm i.d., 0.25 µm film thickness,) as described in detail by Zito et al. [11].
4.5. Identification of Compounds
Identification of compounds was carried out using the mass spectral libraries FFNSC 2, W9N11,
ESSENTIAL OILS (available in MassFinder 3), and Adams [48]. We only considered compounds which
were present in our digital libraries with a calculated Kovats index ± 10 compared to mass spectra
and/or Kovats retention indices found in NIST11, SciFinder and Pherobase [49] database. Kovats
retention indices were calculated using a series of n-alkanes (C10-C30).
4.6. Cell Lines and Culture Conditions
The HL-60 cells were obtained from ATCC® (CCL-240, Rockville, MD, USA), while its
variant HL-60R, was selected for multidrug resistance (MDR) by exposure to gradually increasing
concentrations of doxorubicin. The cells were routinely maintained in Roswell Park Memorial Institute
(RPMI) 1640 (HyClone Europe Ltd., Cramlington, UK) supplemented with 10% heat-inactivated fetal
calf serum, 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin (all reagents were
from HyClone Europe) in a humidified atmosphere at 37 ◦C in 5% CO2.
4.7. Cell Growth Inhibition Assays
The cells were seeded at 1 × 104 cells/well into 96-well plates and then incubated overnight.
At time 0, the medium was replaced with complete, fresh medium, and the essential
oils were added in various concentrations. After 72 h, 15 µL of a commercial
solution (obtained from Promega Corporation, Madison, WI, USA) containing
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) and
phenazine ethosulfate were added. The plates were incubated for 2 h in a humidified atmosphere at 37 ◦C
in 5% CO2. The bioreduction of the MTS dye was assessed by measuring the absorbance of each well at
490 nm. Cytotoxicity was expressed as a percentage of the absorbance measured in the control cells.
4.8. Evaluation of Cell Death by Flow Cytometry
Cells were washed twice with ice-cold PBS and then resuspended at 1 × 106/mL in a hypotonic
fluorochrome solution containing propidium iodide (PI) 50 µg/mL in 0.1% sodium citrate plus 0.03%
(v/v) Nonidet P-40. After 1 h of incubation in this solution, the samples were filtered through nylon
cloth, 40µm mesh, and their fluorescence was analyzed as single-parameter frequency histograms using
a FACSort instrument (Becton Dickinson, Mountain View, CA, USA). The data were analyzed with
CellQuest™ (Becton Dickinson, Mountain View, CA, USA). Cell death was determined by evaluating
the percentage of events accumulated in the preG0-G1 position analyzed by flow cytometry.
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4.9. NF-κB Activation
The DNA binding capacity of NF-κB (p65 subunit) was measured in the nuclear extracts of
cells treated using the TransAM NF-κB and Nuclear ExtractTM Kits (Active Motif, Carlsbad, CA,
USA) according to the manufacturer’s instructions and as previously described [11]. The results
were expressed as arbitrary units: One unit is the DNA binding capacity shown by 2.5 µg of whole
cell extract from Jurkat cells stimulated with 12-Otetradecanoylphorbol-13-acetate (TPA)+calcium
ionophore (CI)/µg protein of HL-60/R nuclear extracts.
4.10. Extraction of Cellular RNA and Reverse Transcription-Quantitative PCR (RT-qPCR)
Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen Life Technologies,
Carlsband, CA, USA). For the evaluation of gene expression, RNA was reverse transcribed using
a high capacity complementary DNA (cDNA) reverse transcription kit (Applied Biosystems Life
Technologies Inc., Foster City, CA, USA). The resulting cDNAs were subjected to real-time RT-PCR
using the TaqMan Gene Expression Master Mix kit (Applied Biosystems Life Technologies Inc., Foster
City, CA, USA) in triplicates. The PCR cycling conditions were as follows: Denaturation at 50 ◦C for
2 min, annealing at 95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 sec and extension at 60 ◦C
for 60 min. The running of the samples and data collection were performed on a StepOne AB Real
Time PCR system (Applied Biosystems Life Technologies Inc., Foster City, CA, USA). β-actin was used
as an internal standard. The specific primers used were: Survivin Hs00153353, XIAP Hs00236913,
Bcl-2 Hs00236329, ABCB1 Hs00184005 (Applied Biosystems Life Technologies Inc., Foster City, CA,
USA). Relative expression was calculated using the comparative Ct method [∆Ct = Ct(target gene)
− Ct(housekeeping gene)]. Where Ct was the fractional cycle number at which the fluorescence of
each sample passed the fixed threshold. Fluorescence was measured at 515–518 nm using StepOne
AB Real Time PCR System software (Applied Biosystems Life Technologies Inc., Foster City, CA,
USA). The ∆∆Ct method was used to determine gene expression levels. ∆∆Ct was calculated using
the formula: ∆∆Ct = ∆Ct(each sample) − ∆Ct(reference sample). Fold change was calculated using the
2-∆∆Ct equation.
4.11. Western Blot Analysis
For Western blot analyses, polyclonal rabbit antibody against XIAP was obtained from Cell
Signaling Technology Inc., Danvers, MA, polyclonal rabbit antibody against survivin from Abcam
Limited, Cambridge, UK; mouse monoclonal antibodies against Bcl-2 were obtained from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA; monoclonal mouse antibody against GAPDH was
obtained from Sigma-Aldrich Srl, Milan, Italy. Whole cellular lysates from HL-60 and HL-60 R
cells were obtained using RIPA buffer (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and
15 µg of protein were subjected to 10% SDS-polyacrylamide gel electrophoresis. Proteins were
electrophoresed onto nitrocellulose membrane (Amersham, Pharmacia Biotech, Milan, Italy) using a
semi-dry fast blot apparatus (Bio-Rad, Milan, Italy). Membranes were blocked with 5% (w/v) BSA in
PBS-0.1% (v/v) Tween 20 for 1 h and then probed with the anti-XIAP (1:500), anti-survivin (1:2000),
anti-Bcl-2 (1:1000), and anti-GAPDH (1:25000) antibodies. Hybridization was visualized using an
enhanced chemiluminescence detection kit (SuperSignal West Femto Maximum Sensitivity Substrate,
Thermo Scientific Life Technologies Italia, Monza, Italy) and the Versa DOC imaging system (BioRad
Laboratories, Milan, Italy). Immunoblots were quantified by densitometry and results were expressed
as arbitrary units (protein/GADPH).
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